Latest Oncology News

HPV-Negative Cervical Cancer: Myth or An Area to Therapeutically Tackle?

January 20th 2021

By Gina Mauro

The idea that HPV-negative cervical cancer is possible, especially in a disease that is mainly driven by HPV positivity, is not a unanimous opinion.

New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward

January 20th 2021

By Jessica Hergert

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

First BCMA-Targeting Therapy Debuts in Multiple Myeloma

January 20th 2021

By Anita T. Shaffer

Sagar Lonial, MD, discussed key facets of belantamab mafodotin and potential next steps.

Trastuzumab Deruxtecan Approved in Europe for HER2+ Metastatic Breast Cancer

January 20th 2021

By Kristi Rosa

January 20, 2021 - The antibody-drug conjugate trastuzumab deruxtecan has been granted conditional approval in the European Union for use as a single agent in the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more HER2-based regimens.

FDA Grants Priority Review to Adjuvant Nivolumab for Resected Esophageal or GEJ Cancer

January 20th 2021

By Kristi Rosa

The FDA has granted priority review to a supplemental biologics license application for nivolumab for use as an adjuvant treatment for patients with resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation treatment.

Latest Oncology Videos

Dr. Hobbs on the Role of Molecular Testing to Determine Resistance in CML

Refining Treatment Approaches for HER2+ Breast Cancer

Dr. Sweet on Key Findings From the OPTIC Trial With Ponatinib in CML

Treatment Approach in Advanced Melanoma

The Role and Rationale for Oral Options in the Treatment of Metastatic Breast Cancer

Dr. Jabbour on Selecting Ponatinib After Second-Generation TKI Failure in CML

Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

Dr. Hari on Treatment Considerations for Relapsed/Refractory Multiple Myeloma

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

The Evolving Landscape in Mantle Cell Lymphoma

Dr. Narla on Advances Made With Precision Medicine in Oncology

Dr. Fonseca on Weighing the Risks With Potential Benefits of Quadruplet Regimens in Myeloma

Dr. Raghav on the Role of Molecular Profiling in Treatment Selection in mCRC

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

Dr. Coleman on Moving Immunotherapy Into Earlier Treatment Lines in Cervical Cancer

Dr. Cortes on the Future of Ponatinib in CML Treatment

Dr. Stiles on Treatment Advances Made in Early-Stage Lung Cancer

Dr. Hong on the Potential Clinical Implications of the SURPASS Trial in Gastric/GEJ Cancer

Dr. Rohs on the Role of Molecular Testing in Lung Cancer Management

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

Rapid Readouts: Updated Efficacy and Safety Data From Phase 1/2 ANCHOR Trial

Dr. Harding on the Results of the SUMMIT Trial in HER2+ Biliary Tract Cancers

Dr. Zhu on the OS Results of the ClarIDHy Trial in IDH1+ Cholangiocarcinoma

All Oncology News

PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

By Maurie Markman, MD

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

FDA Grants Priority Review to Nivolumab/Chemo for Frontline Metastatic Gastric, GEJ, and Esophageal Cancer

January 20th 2021

By Kristi Rosa

January 20, 2021 - The FDA has granted a priority review to a supplemental biologics license application for nivolumab in combination with a fluoropyrimidine- and platinum-containing chemotherapy for use in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

High-Dose Y-90 Pushes the HCC Paradigm Toward Personalized, Multidisciplinary Care

January 20th 2021

By Jessica Hergert

Beau Toskich, MD, discusses the potential of TheraSphere as a therapy in hepatocellular carcinoma, the importance of utilizing a multidisciplinary approach among novel radiation oncology agents, and his hope for a future prospective clinical trial evaluating Y-90.

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL

January 19th 2021

By Jessica Hergert

Jakub Svoboda, MD, discusses the results of the ECHELON-2 trial and explained where clinical research is headed in peripheral T-cell lymphoma.

Emerging Strategies Seek to Build on the Benefit Achieved With Radiation in Lung Cancer

January 19th 2021

By Erica DiNapoli

Katie Keane, MD, highlights the evolving role of stereotactic body radiation therapy in the treatment of patients with stage I lung cancer, the utilization of immunotherapy with chemoradiation in stage III disease, and research evaluating radiation in those with oligometastatic disease.

Imetelstat Has Disease-Modifying Activity in Relapsed/Refractory Myelofibrosis, as Shown by Effect on Telomerase Activity

January 19th 2021

By Wayne Kuznar

January 19, 2021 - Imetelstat exhibited dose-dependent inhibition of the telomerase target, as evaluated by reductions in telomerase activity, human reverse transcriptase levels, and telomere length, in patients with relapsed/refractory myelofibrosis who were enrolled in the phase 2 IMbark trial.

FDA Grants Premarket Approval to Diagnostic Breast Cancer Imaging Technology

January 19th 2021

By Kristi Rosa

January 19, 2021 - The FDA’s Center for Devices and Radiological Health has granted premarket approval to diagnostic breast cancer imaging technology developed by Seno Medical Instruments to assist in the differentiation between benign and malignant breast lesions in patients.

FDA Grants Priority Review to Narsoplimab for HSCT-TMA

January 19th 2021

By Kristi Rosa

January 19, 2021 — The FDA has granted priority review to the biologics license application for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Expert Sees Need for Better Guideline Adherence in NSCLC

January 19th 2021

By Larry Hanover

At the beginning of his career as a medical oncologist in the 1990s, lung cancer specialist Rogerio C. Lilenbaum, MD, was squarely focused on diagnosing and treating his patients while translating emerging clinical research into practice.

Pandemic Inspires New Outreach Program

January 19th 2021

By Mitchell C. Posner, MD,

As oncologists, we are here to help patients and their families as much as we can. That is why we went into cancer medicine. It is what we do every day. Until the coronavirus disease 2019 pandemic knocked on our doors.

Pursuing Pairings of Targeted Agents and HMAs in AML

January 19th 2021

By Caroline Seymour

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

Capitalizing on Cellular Therapies in Lymphoma and Myeloma

January 18th 2021

By OncLive Staff

In our exclusive interview, Dr. Kansagra, Dr. D’Souza, and Dr. Dholaria provided an in-depth look into the current state of cellular therapy in hematologic malignancies, the benefits and drawbacks of approved and investigational products, and new constructs for CAR T in multiple myeloma and lymphoma.

FDA Grants Fast Track Status to Padeliporfin ImPACT for Upper-Tract Urothelial Cancer

January 18th 2021

By Kristi Rosa

January 18, 2021 — The FDA has granted a fast track designation to padeliporfin Immune Photo Activated Cancer Therapy for use in the treatment of patients with low-grade and unifocal upper-tract urothelial cancer.

Embracing the Charm of Uncertainty in Lung Cancer Research

January 18th 2021

By Kathleen O’Brien

Tony S.K. Mok, MD's, early research tackled a grab bag of topics, including pancreatic, colon, and lung cancers, as he tried to catch up with his colleagues.

Next-Generation AR Inhibitors Retain their Role in Nonmetastatic CRPC

January 18th 2021

By Caroline Seymour

Despite the availability of next-generation PET imaging modalities that can detect metastasis earlier, apalutamide, enzalutamide, and darolutamide remain the standard of care for patients with nonmetastatic castration-resistant prostate cancer who have a prostate-specific antigen doubling time of less than 10 months.

See All News